Elysium Health (Index)

Overview

Elysium Health Index is the academically-pedigreed accessible epigenetic biological age test — manufactured by Elysium Health (founded 2014, NYC), co-developed with Yale researcher Morgan Levine (one of the most-cited researchers in the biological-age field). The structural positioning combines two value claims: strongest single-academic-affiliation in consumer epigenetic testing + most accessible pricing among legitimate epigenetic clocks at $299.

The structural value claim is genuine: Elysium delivers Yale-academically-co-developed epigenetic testing at sub-$300 pricing, with a published validation in Nature Aging covering the APEX (Algorithmic Platform for Epigenetic Examination) noise-reduction approach. For consumers who want serious epigenetic testing without TruDiagnostic’s $399–799 premium tier, Elysium is structurally the leading choice in the accessible-epigenetic category.

The structural editorial caveats are real: saliva-based methodology is inherently less accurate than blood-based tests (TruDiagnostic uses blood); ~100k CpG sites is 9× fewer than TruDiagnostic’s ~950k; and 6-week turnaround is the longest in the category. The trade-offs reflect Elysium’s positioning — accessible epigenetic testing requires methodology compromises that comprehensive premium-tier alternatives don’t make.

What We Measured

Note: This review is based on Elysium Health’s published Index methodology, Morgan Levine / Yale collaboration documentation, Nature Aging validation publication, APEX noise-reduction technology claims, saliva-collection workflow, and aggregated user reports. Hands-on testing of the collection experience and 6-week turnaround timing is pending.

The Morgan Levine / Yale academic pedigree

This is the structural credibility differentiator. Morgan Levine is one of the most-cited researchers in the biological-age field — co-developer of multiple biological-age clocks (PhenoAge among them) with extensive peer-reviewed publications. Her involvement with Elysium Index represents direct academic-research credibility:

• Co-developed methodology: not just “advisor” but actual scientific collaboration
• Yale affiliation: published research backing the approach
• Continued involvement: ongoing scientific direction at Elysium
• Nature Aging publication: peer-reviewed validation of APEX precision claims

For comparison:

• TruDiagnostic: Harvard / Yale researcher partnerships, multi-clock approach, broader academic backing
• GlycanAge: Newcastle University origin, glycan-specific research depth
• MyDNAge: epigenetic methodology with thinner academic credit
• Elysium: Morgan Levine / Yale single-lead partnership with strong individual credibility

For users prioritizing specific named-researcher academic backing, Elysium’s Morgan Levine partnership is structurally distinctive. For users prioritizing breadth of academic backing across institutions, TruDiagnostic is structurally better.

The APEX noise-reduction technology

This is the central technical claim. Elysium’s APEX (Algorithmic Platform for Epigenetic Examination) uses custom Illumina chip + algorithmic noise reduction to claim ~1-year variation on saliva vs typical 25-year saliva variance:

• Standard saliva methylation tests: high variance (~25 years) due to noise in saliva methylation signal
• Elysium APEX: claims ~1-year variance via algorithmic noise reduction
• Validation: published in Nature Aging

The honest editorial framing: the precision claim is meaningfully validated by Nature Aging publication. The methodology represents real algorithmic innovation in saliva-based epigenetic testing. However: even with APEX precision improvements, blood-based testing (TruDiagnostic) inherently captures more epigenetic signal than saliva-based testing. APEX makes saliva testing meaningfully more precise; it doesn’t make saliva better than blood for absolute signal capture.

The 10 aging dimensions

Elysium Index measures:

• Overall biological age
• Cumulative aging rate (how fast you’re aging)
• 9 organ-system ages: brain, heart, metabolic, immune, inflammation, kidney, liver, hormone, blood

For comparison:

• TruDiagnostic TruAge: 11 organ-system ages + multi-clock approach (OMICmAge, SYMPHONYAge, DunedinPACE)
• GlycanAge: single immune-aging score (no organ-system breakdown)
• InsideTracker InnerAge: single biological-age score (no organ-system breakdown)

Elysium’s 10-dimension breakdown is structurally similar to TruDiagnostic’s 11-system approach at substantially lower price. For users wanting organ-system biological age tracking at accessible pricing, Elysium is structurally the leading choice.

The saliva-vs-blood methodology trade-off

This is the central technical caveat. Saliva-based testing has known limitations vs blood-based testing:

• Fewer cell types in saliva vs blood (less methylation signal diversity)
• Higher inter-collection variance in saliva vs blood
• Different epigenetic signature between tissues (saliva ≠ blood ≠ buccal cells)

Elysium addresses these limitations via APEX algorithmic improvements. The honest framing: APEX makes Elysium’s saliva-based testing meaningfully more reliable than naive saliva testing — but doesn’t fully close the gap with blood-based testing. For absolute epigenetic signal capture, blood is structurally better; for accessible saliva-based testing, Elysium’s APEX is the leading choice.

The 6-week turnaround timing

Elysium’s 6-week turnaround is the longest in the bio-age testing category:

• TruDiagnostic: ~3-4 weeks (sometimes longer)
• GlycanAge: ~3-4 weeks
• MyDNAge: ~4-5 weeks
• InsideTracker InnerAge: ~3-5 days
• Elysium: ~6 weeks

For users running active intervention protocols and wanting fast feedback, the 6-week wait is meaningfully slower than alternatives. For users running annual longevity-tracking, 6 weeks is acceptable.

The 100+ science-based recommendations

Elysium provides 100+ lifestyle recommendations based on results. The recommendations span:

• Nutrition specifics
• Exercise protocols
• Sleep optimization
• Stress management
• Supplement guidance (some Elysium products, some general)

The recommendations are algorithmic, not personalized clinician interpretation. Compare:

• GlycanAge: 30-minute 1-on-1 physician consultation
• TruDiagnostic: 85+ page personalized report (algorithmic + structured)
• Elysium: 100+ algorithmic recommendations
• MyDNAge: report-only

For users who value clinician interpretation, GlycanAge is structurally better. For users who prefer algorithmic recommendations and self-direction, Elysium’s structure is workflow-friendly.

3-Year Cost of Ownership

Use case	Cost
Single test	~$299
Annual retest	~$897 / 3 yr
Bi-annual retest	~$598 / 3 yr

Compare: TruDiagnostic ($399–799 per test), GlycanAge ($348 per test, $599 annual), MyDNAge (~$299 per test), InsideTracker InnerAge ($99 add-on within bloodwork).

Elysium’s pricing is structurally accessible — meaningfully cheaper than TruDiagnostic and GlycanAge at the test-per-test level. The 6-week turnaround is the operational trade-off; the cost advantage is real.

Regulatory Status

Not FDA-Cleared. Standard for the bio-age testing category. Lab developed test framework; CLIA-certified lab partner credentials.

When Elysium Index Makes Sense — And When It Doesn’t

Strong fit:

• You want academically-pedigreed epigenetic testing without TruDiagnostic premium pricing
• You value Morgan Levine / Yale academic backing as a specific credibility signal
• You prefer saliva collection over venous blood draw
• You want organ-system aging breakdown at accessible pricing
• You’re US-based (Elysium is US-only)

Weaker fit:

• You want highest-resolution epigenetic testing — TruDiagnostic’s 950k CpG + multi-clock is structurally better
• You want fastest results — InsideTracker InnerAge (3-5 days) or others (3-4 weeks) are faster than Elysium’s 6 weeks
• You want physician consultation for results interpretation — GlycanAge is structurally better
• You want inflammation-specific signal — GlycanAge’s glycan methodology is structurally better
• You’re non-US-based — Elysium availability is limited

Verdict: Recommended

Elysium Health Index earns a recommended verdict on the strength of its Morgan Levine / Yale academic co-development partnership (strongest single-academic-affiliation in consumer epigenetic testing), APEX noise-reduction technology with published Nature Aging validation claiming ~1-year variation on saliva, $299 accessible pricing meaningfully below comparable epigenetic alternatives, 10 aging dimensions including 9 organ-system ages, and saliva collection eliminating venous-draw friction.

For buyers seeking academically-pedigreed accessible epigenetic biological age testing, Elysium Index is structurally the leading consumer choice. The combination of Yale / Morgan Levine credibility + APEX precision claims + $299 entry pricing + organ-system breakdown is unmatched at the price point.

For buyers prioritizing highest-resolution comprehensive testing (TruDiagnostic), inflammation-specific signal (GlycanAge), fastest turnaround (InsideTracker InnerAge or others), or physician interpretation (GlycanAge), structurally better alternatives exist. Elysium is the accessible-tier epigenetic specialist with corresponding methodology trade-offs (saliva vs blood, 100k vs 950k CpGs, 6-week vs 3-week turnaround).

The editorial framing: Elysium is what TruDiagnostic looks like at half the price with methodology compromises. For accessible epigenetic testing, the trade-offs are defensible; for maximum-precision epigenetic testing, TruDiagnostic remains structurally better despite the price premium.

Changelog

• 2026-05-06: Initial review published based on Elysium Health Index’s published methodology, Morgan Levine / Yale collaboration documentation, APEX noise-reduction Nature Aging validation publication, and aggregated user-report data.